Overview
Bristol Myers Squibb, headquartered in Princeton, New Jersey, discovers, develops, licenses, manufactures and sells biopharmaceutical products, including small-molecule drugs, biologics and chimeric antigen receptor (CAR-T) cell therapies.[2] Forbes records sales of US$48.5bn, up only 1.8% on the prior-year figure, and profit of US$7.3bn.[2] The slow growth dropped it from ninth to twelfth place as Novo Nordisk and Sanofi overtook it. With 32,500 employees, it runs one of the leaner workforces among the large US drug makers, generating about US$1.5m of sales per employee on Forbes figures.[2] Its market value of US$116.4bn is a little above Sanofi’s.
Bristol Myers Squibb strengths and limitations
Strengths
- High sales per employee
- Established CAR-T cell-therapy business
- Profit margin of 15%
Limitations
- Sales growth of 1.8%
- Fell three places in the ranking
- Exposure to patent expiries
Appears in
Bristol Myers Squibb peers and competitors
Companies ranked in the same lists as Bristol Myers Squibb.
Johnson & Johnson
Takeda Pharmaceutical
Daiichi Sankyo- Astellas Pharma
Viatris- Regeneron Pharmaceuticals
- CSL
Otsuka Holdings- Teva Pharmaceutical
Merck KGaA
Gilead Sciences- Amgen
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.